Jonathan Freeman, Ph.D.
Chief Business Officer
Jonathan Freeman is Vedanta's Chief Business Officer. An industry veteran, Jonathan joined Vedanta following a career spanning two decades in leading roles within Merck KGaA, Baxter and Serono. Within Merck, Jonathan served as Senior Vice President, Head of Strategy Development and Portfolio Management, overseeing asset valuation, capital allocation, and strategy development guiding investment and corporate shifts resulting in, amongst other things, the launch of Bavencio in collaboration with Pfizer. Prior to Merck, Jonathan was Director of European M&A for Baxter, where he defined and executed external growth strategy, established commercial and manufacturing joint ventures, constructed, financed, and executed strategic business models and alliances working alongside multinational investment groups such as TPG and Goldman Sachs. During his time with Serono, Jonathan was Director of Corporate and Business Development, leading licensing, alliance management, the management of private equity relationships, and participating broadly in Corporate M&A. Jonathan was a former Vice President of the Swiss Pharma Licensing Group (now SwissHLG), representative to the International Pharma Society, a faculty member of the European Centre for Pharmaceutical Medicine (ECPM), and an Editor of the Business Development & Licensing Journal. Jonathan holds a First Class Honours BA in Biochemistry and an MA from Cambridge University, a Ph.D. in Molecular Pharmacology from the Imperial Cancer Research Fund (now CRUK) at the Edinburgh University Medical School, and an MBA from Geneva and Webster, St Louis Universities. Prior to entering the industry, Jonathan held assistant professor and post-doctoral positions in cancer research, gene therapy and virology in several leading academic settings including the Swiss Institute for Cancer Research (ISREC) and the Geneva Medical School (CMU) obtaining funding from the European Molecular Biology Laboratory (EMBL) and the Royal Society of London.